Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q1 2022 call → NOThe question asks whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket — with three conditions: (1) The company is paying now for something not yet earning. (2) Management speaks as though the wait is the company's main current work. (3) The far side is a specific, near-dated, already-visible event. Let me review the transcript for evidence. Key candidates: - The Zio monitor (next-generation biosensor) — they shipped the first batch for first patient use following regulatory clearance. Full-scale commercialization and conversion anticipated in 2023. This is a product transition, but is it described as a current cost burden? They mention it will replace Zio XT, provide improved form factor, reduced cost profile. But they don't describe current costs being absorbed for it in a way that lands in results. - International expansion — Germany, France, Netherlands, Sweden market access initiatives commencing in coming months. Japan — initiating reimbursement and regulatory pathways within next few months, commercial launch by first half of 2024. These are future initiatives, not currently being paid for with costs landing in results. - The Zio Watch — pending FDA clearance, market evaluation phase early next year. Not yet cleared. - The NGS reimbursement — they have an IDTF in suburban Chicago, they're sending claims over, need to get systems configured. This is more of a reimbursement optimization, not a waiting period with costs. - The Verily milestone — they mention milestone expenses to Verily that did not reoccur in Q1, next milestone in 2023. This is a past expense, not current. - Restructuring charges — $26.6 million in Q1 for reducing San Francisco facility. This is a cost reduction, not a waiting period. Let me look for something where they're paying now for something not yet earning. The Zio monitor: "we are very pleased to announce that we have shipped the first batch of our next-generation biosensor, the Zio monitor for first patient use following regulatory clearance. This monitor will eventually replace Zio XT while providing a platform that delivers a dramatically smaller form factor, resulting in an improved patient experience and a reduced cost profile with greater efficiencies for manufacturability and scalability without sacrificing our quality of service.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.